Literature DB >> 14994385

Erythromycin suppresses the expression of cyclooxygenase-2 in rheumatoid synovial cells.

Takehide Fumimori1, Seiyo Honda, Kiyoshi Migita, Minako Hamada, Taro Yoshimuta, Junichi Honda, Takaaki Fukuda, Ritsu Suzuki, Masafumi Gotoh, Katsumi Eguchi, Hisamichi Aizawa.   

Abstract

OBJECTIVE: To investigate whether erythromycin (EM) can suppress the expression of cyclooxygenase-2 (COX-2) in rheumatoid synovial cells, and determine the mechanisms involved. Methods. Synovial tissues were obtained from 25 patients with rheumatoid arthritis (RA). Rheumatoid synovial cells were cultured with or without EM (0.1-1000 nM) in the presence of interleukin 1beta (IL-1beta) for various times. Protein expression of COX-2, and phosphorylation of extracellular signal regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (p38 MAPK) were detected by Western blot. COX-2 messenger RNA (mRNA) was detected by RT-PCR. DNA binding activity of nuclear factor kappa B (NF-kB) was detected by ELISA. Results. IL-1beta-stimulated synovial cells expressed COX-2 protein. EM suppressed the IL-1beta-induced COX-2 protein expression in a dose-dependent manner and inhibited IL-1beta-induced p38 MAPK phosphorylation, which was correlated with COX-2 expression in synovial cells. In contrast, EM had no effect on DNA binding activity of NF-kB and ERK1/2 expression.
CONCLUSION: Our results indicated that EM downregulated COX-2 expression by inhibiting the p38 MAPK cascade, but had no effect on NF-kB or ERK1/2, in rheumatoid synovial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14994385

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome.

Authors:  Keith K Burkhart; Darrell Abernethy; David Jackson
Journal:  J Med Toxicol       Date:  2015-06

Review 2.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  The Chondroprotective Role of Erythromycin in a Murine Joint Destruction Model.

Authors:  Tomoya Uchimura; Andrea T Foote; David C Markel; Weiping Ren; Li Zeng
Journal:  Cartilage       Date:  2016-02-17       Impact factor: 4.634

4.  Molecularly imprinted polymer nanocarriers for sustained release of erythromycin.

Authors:  Henrik Kempe; Anna Parareda Pujolràs; Maria Kempe
Journal:  Pharm Res       Date:  2014-08-08       Impact factor: 4.200

5.  Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors.

Authors:  Takahiro Hamoya; Shingo Miyamoto; Susumu Tomono; Gen Fujii; Ruri Nakanishi; Masami Komiya; Shuya Tamura; Kyoko Fujimoto; Jiro Toshima; Keiji Wakabayashi; Michihiro Mutoh
Journal:  J Clin Biochem Nutr       Date:  2017-04-14       Impact factor: 3.114

Review 6.  Macrolide therapy in chronic inflammatory diseases.

Authors:  Brygida Kwiatkowska; Maria Maślińska
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

7.  A flow cytometry technique to study intracellular signals NF-kappaB and STAT3 in peripheral blood mononuclear cells.

Authors:  Sandrine Lafarge; Hind Hamzeh-Cognasse; Patricia Chavarin; Christian Genin; Olivier Garraud; Fabrice Cognasse
Journal:  BMC Mol Biol       Date:  2007-07-31       Impact factor: 2.946

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.